Prognostic significance of residual mass at the end of therapy in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS) IV experience
Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 8501-8501
10.1200/jco.2005.23.16_suppl.8501